BenevolentAI: Appointment of Adviser

LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of

Businesswire13:00

Morgan Stanley Starts Absci at Overweight, Cites AI Theme

Seeking AlphaJul 3 22:51

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

TipRanksJul 3 21:26

Sanofi's blockbuster drug Dupixent has been approved in Europe to treat pulmonary diseases.

Zhītōng Cáijīng APP learned that sanofi (SNY.US) heavyweight drug Dupixent has been approved for use in European patients with chronic lung disease, opening up a new path of growth. According to a statement from the company on Wednesday, European regulators became the first in the world to approve the vaccine as an additional treatment for patients with chronic obstructive pulmonary disease (some with high levels of white blood cells). In two milestone studies, the drug reduced disease progression, improved lung function, and improved quality of life. The decision makes Dupixent a treatment option for approximately 220,000 adult CO patients in the European Union.

Zhitong FinanceJul 3 14:53

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

Zacks Jul 2 22:30

Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.

Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.

BenzingaJul 2 22:12